Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix, Inc. reports developments as a diagnostics solutions company focused on lung disease testing and biopharma development services. Its updates center on Diagnostic Tests such as Nodify Lung® Nodule Risk Assessment, Nodify CDT® and IQLung® Cancer Treatment Guidance, along with blood- and tissue-based testing, proteomic and genomic approaches, and development work for life sciences partners.
Recurring news also covers quarterly results, revenue guidance, test-volume trends, clinical validation studies, real-world evidence presentations at medical meetings, and the company’s efforts to expand evidence for lung nodule management and oncology testing applications.
Biodesix (Nasdaq:BDSX) will present new real-world clinical and economic data on its Nodify Lung blood-based testing strategy at the American Thoracic Society 2026 meeting in Orlando, May 15–20, 2026.
Multiple oral and poster sessions highlight lung nodule risk stratification, diagnostic lead time, and stage shift in community hospitals.
Biodesix (NASDAQ: BDSX) reported Q1 2026 results: $25.6M revenue (+42% YoY), $22.3M Diagnostic Testing revenue (+37% YoY), and Development Services revenue of $3.3M (+99% YoY). Gross margin was 84% (82% excl. $0.4M one-time recovery). Net loss improved to $7.8M; Adjusted EBITDA loss was $4.1M. Cash and equivalents were $25.6M, up 35% from Dec 31, 2025, including $16.8M net ATM proceeds. Full-year 2026 revenue guidance raised to $108–114M (midpoint ≈25% growth). Conference call and webcast held May 4, 2026 at 4:30 p.m. ET.
Biodesix (Nasdaq: BDSX) will report first quarter 2026 financial results for the period ended March 31, 2026, after market close on Monday, May 4, 2026.
Management will host a conference call and webcast at 4:30 p.m. ET on May 4 to discuss results and provide a business update; listeners can register for the webcast and analysts can join the live call with the provided dial-in and passcode.
Biodesix (NASDAQ: BDSX) announced it received the 2026 USA TODAY Top Workplaces award on April 9, 2026, marking the company's third consecutive year of recognition.
The award, based on confidential employee surveys by Energage, highlights strong employee engagement, meaningful work, and a people-first culture that leadership says supports high performance and patient impact.
Biodesix (Nasdaq: BDSX) will present seven abstracts, including two oral sessions, at the AACR Annual Meeting in San Diego from April 17–22, 2026. Presentations cover blood- and tissue-based testing, tumor and immune profiling, a validated myeloid NGS panel, and multi-omic MRD pipeline development.
Highlighted technologies include mass spectrometry, Bio-Rad ddPCR, Thermo Fisher Ion AmpliSeq and Ion Torrent Genexus workflows, with partners Thermo Fisher, Bio-Rad and Memorial Sloan Kettering co-presenting MRD data.
Biodesix (Nasdaq: BDSX) announced publication of the largest lung nodule biomarker validation: a retrospective pooled analysis of 1,100 patients with 4–30 mm noncalcified nodules. The Nodify CDT test showed high specificity of 91–97% across nodule sizes, four studies and 48 US clinical practices.
Results include data from the real-world CLARIFY study (NCT06728319) and support clinical use of Nodify CDT as a decision-support tool for earlier lung cancer diagnosis.
Biodesix (NASDAQ: BDSX) reported strong Q4 2025 results with $28.8M revenue, 83% Q4 gross margin, and the company’s first-ever positive Adjusted EBITDA of $0.5M. Fiscal 2025 revenue was $88.5M (+24% YoY) and net loss improved to $35.3M.
The company finished with pro forma cash of $33.7M (including ATM), amended its term loan to November 2028, and guided FY2026 revenue to $106–112M (midpoint +23%).
Biodesix (Nasdaq: BDSX) said members of management will present at two investor conferences in March 2026: TD Cowen’s 46th Annual Health Care Conference and Barclays’ 28th Annual Global Healthcare Conference.
Fireside chats are scheduled for March 3, 2026 at 2:30 PM ET in Boston and March 11, 2026 at 12:00 PM ET in Miami, and will be webcast live with replays available on the company’s Investors site.
Biodesix (Nasdaq: BDSX) will report fourth-quarter and full-year 2025 financial results after market close on Thursday, February 26, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern Time the same day to review results and provide a business update.
A live webcast will be available with registration via the company’s investor site, a replay posted about two hours after the call, and participants are advised to join 15 minutes early.
Biodesix (Nasdaq: BDSX) reported preliminary, unaudited results for Q4 and full-year 2025. Estimated Q4 revenue $28.8M (+41% YoY) and FY2025 revenue $88.5M (+24% YoY), above prior guidance range of $84–$86M. Lung Diagnostics revenue estimated at $25.2M (Q4) and $79.2M (FY), driven by higher test volumes, price per test, and ~$1.0M in collections on claims >1 year. Test volumes were an estimated 18,000 (Q4) and 62,600 (FY). Development Services revenue was estimated at $3.6M (Q4) and $9.3M (FY). Cash and cash equivalents were ~$19.0M at 12/31/2025, including $2.3M of at-the-market proceeds. The company affirmed its expectation of positive Adjusted EBITDA in Q4 2025. Results remain preliminary and subject to audit.